Atezolizumab did not confer any benefits when added to SBRT in a phase 3 trial of patients with inoperable, early-stage NSCLC.

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease recurrence and death rate by 50 ...

Adding atezolizumab to standard adjuvant chemotherapy significantly delayed recurrence or death for individuals with stage III deficient mismatch repair colon cancer, according to findings presented ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

Small-cell lung cancer (SCLC) is one of the most lethal cancers, with patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) experiencing a median survival of just 12 months after ...

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

The risk of recurrence or death after surgery for deficient mismatch repair (dMMR) colon cancer decreased by 50% in patients who received immunotherapy in addition to adjuvant chemotherapy, a large ...

In the Zepzelca plus atezolizumab and atezolizumab arms, respectively, treatment-related adverse events (TRAEs) occurred in 83.5% versus 40.0% of patients, with Grade 3-4 TRAEs in 25.6% versus 5.8 ...